Endovascular Treatment, Vertebrobasilar Artery Occlusion
Conditions
Keywords
Acute Ischemic Stroke, Vertebrobasilar Artery Occlusion, Endovascular Treatment
Brief summary
This multicenter, prospective, open-label randomized controlled trial with blinded assessment was designed to assess the efficacy and safety of endovascular treatment for progressive stroke due to vertebrobasilar artery occlusion.
Detailed description
This multicenter, prospective, open-label, randomized controlled trial with blinded endpoint assessment (PROBE design) was designed to evaluate endovascular treatment (EVT) in patients with progressive stroke due to vertebrobasilar artery occlusion (VBAO). Progressive stroke due to VBAO was defined as vertebrobasilar artery occlusion confirmed by CTA, MRA, or DSA, accompanied by neurological deterioration occurring between 24 hours and 14 days after symptom onset, defined as an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score resulting in a total NIHSS score ≥10 in patients with an initial NIHSS score \<10. Participants will be randomly assigned in a 1:1 ratio to receive EVT plus medical therapy or medical therapy alone. The primary endpoint is the proportion of patients with good functional outcome at 90 days, defined as a modified Rankin Scale (mRS) score of 0 to 3. Secondary outcomes include the distribution of mRS scores at 90 days, all-cause mortality at 90 days, and the incidence of symptomatic intracranial hemorrhage (sICH).
Interventions
PROCEDUREEndovascular Recanalization
The endovascular approach is selected by the treating neurointerventionalists based on angiographic findings, occlusion characteristics, and procedural feasibility. Permitted techniques include mechanical thrombectomy using stent retriever and/or aspiration-based methods. Adjunctive endovascular procedures, such as balloon angioplasty, stent deployment, or intraarterial thrombolysis, may be used when deemed necessary to achieve or maintain vessel patency. Angiographic reperfusion is assessed during the procedure, and treatment is terminated once adequate revascularization is obtained. Subsequent medical therapy is individualized according to stroke mechanism, procedural findings, and post-treatment imaging.
Medical therapy consists of comprehensive evidence-based medical therapy for acute ischemic stroke, encompassing acute supportive care, neurological and physiological monitoring, etiological evaluation, and secondary prevention strategies. Standard pharmacological treatments are administered as appropriate, together with risk factor modification and supportive care measures, in accordance with current guideline recommendations. Endovascular recanalization procedures are not included in this treatment strategy.
Sponsors
Feng Gao
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years. 2. Acute ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of \<10 at initial symptom onset, and no prior endovascular treatment. 3. Stroke progression occurring from 24 hours to 14 days after initial symptom onset, defined as an NIHSS score of ≥10 with an increase of ≥4 points from baseline. 4. Acute basilar artery occlusion or dominant vertebral artery occlusion with contralateral occlusion or hypoplasia, confirmed by CTA, MRA or DSA. 5. Posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS) of ≥6 and Pons-Midbrain Index (PMI) of ≤3 on CT or diffusion-weighted imaging (DWI). 6. Randomization within 24 hours of stroke progression. 7. Pre-stroke mRS score of 0-2. 8. Provision of signed informed consent by the patient or their legal representative.
Exclusion criteria
1. Any sign of intracranial hemorrhage (except microbleeds) on baseline brain imaging. 2. Imaging confirms the progression of symptoms caused by intracranial hemorrhage, brain edema, or other clear causes. 3. Extensive cerebellar infarction with significant mass effect or bilateral thalamic infarction on baseline neuroimaging. 4. Presence of untreated intracranial aneurysm, intracranial tumor (except small meningioma and aneurysms \<3 mm in diameter), or intracranial arteriovenous malformation. 5. Known or highly suspected chronic responsible artery occlusion. 6. Presence of severe stenosis in the extracranial or intracranial segment of the responsible artery, arterial dissection, or excessive vascular tortuosity that may prevent successful delivery or navigation of endovascular devices. 7. Known contraindication to contrast medium (except mild rash). 8. Refractory hypertension not controlled by medication, defined as systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg. 9. Known pregnancy or lactation, or a positive pregnancy test prior to randomization. 10. Known dementia or psychiatric disease precluding completion of neurological assessment and follow-up. 11. Life expectancy \<1 year, including patients with malignancy or advanced cardiopulmonary disease. 12. Current participation in any other clinical trial of drugs or medical devices, or anticipated participation in another such trial within 3 months after enrollment. 13. Acute ischemic stroke within 48 hours after cardiovascular or cerebrovascular interventional treatment or major surgery; patients presenting \>48 hours after such procedures were eligible. 14. Recent (within 1 month) gastrointestinal or genitourinary bleeding, acute myocardial infarction, or traumatic brain injury. 15. Multivessel severe stenosis or occlusion confirmed by CTA, MRA, or DSA. 16. Known or suspected central nervous system vasculitis. 17. Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, current use of oral anticoagulants with an INR \>1.5, or active bleeding. 18. Blood glucose \<2.8 or \>22.2 mmol/L; platelet count \<100 × 10⁹/L; estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² or serum creatinine ≥177 μmol/L (2.0 mg/dL). 19. Any other condition deemed by the site investigator to make the patient unsuitable for participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of patients achieving modified Rankin Scale (mRS) score 0-3 at 90 days | 90±14 days after randomization | The modified Rankin scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability,5 severe disability, and 6 death. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ordinal shift analysis of mRS score at 90 days after randomization | 90±14 days after randomization | The modified Rankin Scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death. |
| The proportion of patients achieving mRS scores 0-1 and 0-2 at 90 days | 90±14 days after randomization | The modified Rankin Scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death. |
| The National Institutes of Health Stroke Scale (NIHSS) score at 24 hours | 24 (-6/+12) hours after randomization | National Institutes of Health Stroke Scale (NIHSS) score at 24 hours after randomization The National Institute of Health Stroke Scale (NIHSS) ranged from 0 to 42, with higher scores indicating greater neurologic deficits. |
| The NIHSS score at 7 days after randomization or discharge (whichever came first), as well as changes from baseline | 7 days after randomization or at discharge | NIHSS score at 7 days after randomization or discharge (whichever came first) The National Institute of Health Stroke Scale (NIHSS) ranged from 0 to 42, with higher scores indicating greater neurologic deficits. |
| The score on the European Quality of life 5-Dimension 5-Level (EQ-5D-5L) patient-reported questionnaire score at 90 days | 90±14 days after randomization | European Quality of life 5-Dimension 5-Level (EQ-5D-5L) is a standardized instrument for measuring the general health status. Rated level can be coded as a number 1, 2, 3, 4 or 5, which indicates having no problems for 1, having some problems for 2, having moderate problems for 3, having serious problems for 4 and having extreme problems for 5. |
| The proportion of Barthel index 95-100 points at 90 days | 90±14 days after randomization | The proportion of Barthel Index 95-100 at 90 days after randomization. |
| The recanalization of the vertebrobasilar artery at 24 hours after randomization (confirmed by CTA, MRA, DSA, or TCD) | 24 (-6/+12) hours after randomization | The recanalization of the vertebrobasilar artery at 24 hours after randomization (confirmed by CTA, MRA, DSA or TCD). |
| The rate of technical success is defined as the successful recanalization of the target vessel at the end of the procedure (expanded Thrombolysis in Cerebral Infarction scale [eTICI] 2b-3) | At the end of the procedure | Technical success rate, defined as successful recanalization of target vessels at the end of procedure (The expanded Thrombolysis in Cerebral Infarction scale \[eTICI\] 2b-3). |
Countries
China
Contacts
CONTACTFeng Gao, MD
PRINCIPAL_INVESTIGATORFeng Gao, MD
Beijing Tiantan Hospital
Outcome results
None listed